What Effluent Quality Does a Pharmaceutical MBR Actually Deliver?
A submerged membrane bioreactor on a typical API, formulation, or cephalosporin feed delivers an effluent that approaches reuse quality when operating within the correct envelope. The table below compiles the parameters an engineer can defend in front of a regulator or QA director, all sourced from the 2015 SCIRP review of membrane separation on pharmaceutical wastewater.
| Parameter | Pharma MBR effluent (operating window) | Source |
|---|---|---|
| COD | Residual < 50 mg/L after > 99.5% removal | SCIRP 2015, section 2.2 |
| Total N | 5–10 mg/L residual, 85–90% removal | SCIRP 2015, section 2.2 |
| NH3-N (chemical plant train, 72.8–92.4 mg/L feed) | 1.4–4.1 mg/L, 94.5–97.6% removal | SCIRP 2015, section 2.4 |
| TSS / turbidity | Close to zero — solids retained by the membrane | SCIRP 2015, section 3.1 |
| HRT (cephalosporin pilot, > 90% COD removal) | 35 h MBR vs 80 h conventional activated sludge (CAS) | SCIRP 2015, section 3.3 (citing Dry) |
The biology drives the COD and NH3-N numbers, while the membrane drives the TSS and turbidity numbers. Industrial wastewater contains large amounts of suspended material, and the membrane screens them out, so TSS and turbidity of the treated water come close to zero (SCIRP 2015, section 3.1). The > 99.5% COD removal and 85–90% total N removal are an operating window reported by SCIRP 2015 (section 2.2) for a well-controlled pharma plant, and they shift with influent variability across API, formulation, and cephalosporin campaigns. For a deeper look at the spec sheet framing, see MBR effluent quality explained for 2026.
Why MBR Hits Those Numbers on Pharmaceutical Streams
MBR performance on pharmaceutical streams results from three design features stacked together rather than the membrane alone. First, the membrane replaces the secondary clarifier and retains biomass inside the reactor, so mixed liquor suspended solids (MLSS) are sustained at 18,000–19,000 mg/L — roughly 5–10 times what a conventional activated-sludge tank holds (SCIRP 2015, section 2.1, citing reference 7). That high MLSS gives the reactor a higher volumetric removal rate, which is the reason an MBR can match CAS effluent at a fraction of the HRT.
Second, slow-growing nitrifiers stay inside the reactor because the membrane prevents wash-out common in clarifier overflows. The SCIRP 2015 review attributes MBR's high NH3-N removal directly to this retention of nitrifying biomass (section 2.4). Without that retention, the 94.5–97.6% ammonia removal reported on the chemical-plant train would not survive a winter temperature drop or a toxic slug.
Third, refractory organics are held in the reactor for a longer effective solids retention time (SRT), which improves the breakdown of hard-to-biodegrade API intermediates and solvents (SCIRP 2015, section 3.3). The membrane itself, typically microfiltration or ultrafiltration at less than 1 μm, does not act on dissolved APIs — that work is performed by the biomass. The membrane's job is to physically retain solids, colloids, and biomass so the biological step can run at the high MLSS and long SRT that produce the SCIRP 2015 effluent numbers. A packaged example is the HydropureWater integrated MBR system, which combines activated sludge with a submerged PVDF membrane in a single tank.
Cephalosporin and Chemical-Plant Data: Real Operating Numbers
Two peer-reviewed cases anchor any sizing exercise for pharmaceutical MBR, both sourced from the SCIRP 2015 review. These examples demonstrate how MBR capabilities translate to specific pharmaceutical wastewater challenges.
The first is the cephalosporin pilot. Dry assembled a 300 L MBR and ran it on cephalosporin pharmaceutical wastewater against a conventional activated-sludge baseline on the same feed. At greater than 90% COD removal, the conventional activated-sludge process needed 80 hours of hydraulic retention time; the MBR achieved the same COD removal in 35 hours (SCIRP 2015, section 3.3, citing reference 5). That is a 2.3× reduction in HRT at matched effluent quality, explaining why engineers select MBR for cephalosporin plant retrofits where the existing aeration tank is the bottleneck.
The second is a chemical-plant train running activated sludge followed by hydrolysis–acidification and an MBR polish. Influent ammonia of 72.8–92.4 mg/L dropped to 1.4–4.1 mg/L in the MBR effluent, a total ammonia removal of 94.5–97.6% (SCIRP 2015, section 2.4). The biology did this work, while the membrane's role was to keep the nitrifiers in the reactor.
For sizing context, SCIRP 2015 (section 2.2) reports water intensity at a medium-sized pharmaceutical factory of 3.5–5 m³ per tonne of product, equivalent to 6,000–8,000 m³ of wastewater per day. These are the two anchor cases to size against when the influent profile is similar: cephalosporin-strength feed for the HRT question, ammonia-laden chemical-plant feed for the nitrification question. The full design framing is laid out in the submerged MBR pharmaceutical wastewater guide.
MBR vs Conventional Activated Sludge on Pharma Feed
MBR and conventional activated sludge behave differently on pharma feeds that fluctuate with production campaigns. The comparison below uses SCIRP 2015 data.
| Parameter | MBR | Conventional activated sludge (CAS) | Source |
|---|---|---|---|
| HRT to reach > 90% COD on cephalosporin feed | 35 h | 80 h | SCIRP 2015, section 3.3 |
| MLSS in aeration tank | 18,000–19,000 mg/L | Typically a few thousand mg/L | SCIRP 2015, section 2.1 (ref 7) |
| Risk of sludge bulking loss | Low — no settler to lose | High on toxic or inhibitory pharma batches | SCIRP 2015, section 3.2 |
| NH3-N retention mechanism | Membrane retains slow-growing nitrifiers in reactor | Nitrifiers washed out unless SRT is held high | SCIRP 2015, section 2.4 |
| Added OPEX vs CAS | Membrane fouling control, air-scour energy, periodic chemical clean | None of the above | SCIRP 2015, sections 2.1 and 3.1 |
The MLSS and HRT gains provide real estate and stability. The trade-off is the membrane operation envelope — fouling control, air-scour energy, and periodic chemical cleaning are new operating costs that CAS does not carry. The MBR system design criteria 2026 guide walks through how to budget for these on a working plant.
When MBR Effluent Is Enough — and When You Need a Polish Step
An MBR run at the SCIRP 2015 benchmark envelope is generally defensible for discharge limits involving COD, BOD, TSS, NH3-N, and total N. The membrane pushes TSS and turbidity close to zero, the biology drives COD and ammonia down to the residuals in the table above, and the clarifier failure mode is eliminated. For many municipal and state discharge permits, this suffices.
Trace APIs require additional treatment. A 2025 Molecules study evaluated g-C3N4/rGO photocatalysis on real MBR-treated wastewater spiked with carbamazepine, diclofenac, ibuprofen, and sulfamethoxazole at 50 mg/L each. Diclofenac and sulfamethoxazole were removed completely within 30 minutes; the nanocomposite added roughly 19% ibuprofen degradation and 13% carbamazepine degradation over UV alone (Molecules 2025). MBR effluent carries biologically recalcitrant pharmaceuticals, necessitating a polish step when trace APIs are in scope.
The decision rule of thumb is to place RO or UF downstream of the MBR for cooling-tower make-up, boiler feed, or process-rinse reuse. The DF series PVDF flat sheet membrane module at 0.1 μm is sized to feed such a polish step, and the HydropureWater industrial RO system is the next stage. Target strict trace-API discharge limits by budgeting for an advanced oxidation or activated-carbon polish. SCIRP 2015 frames trace-compound removal as the next research and engineering direction for pharmaceutical MBR.
Sizing and Operating Parameters to Lock In
Translating bench data into a defensible plant design starts with locking in the right inputs. The checklist below uses only parameters that appear in the supplied research.
| Design input | What to lock in | Source / status |
|---|---|---|
| Influent characterization | COD, BOD, NH3-N, sulfate, suspended solids, and the list of active ingredients expected on site | SCIRP 2015, section 2.2 — pharma flows vary sharply with production campaign |
| HRT starting point | ~35 h for cephalosporin-strength feed at > 90% COD removal | SCIRP 2015, section 3.3 (Dry) |
| MLSS envelope | 18,000–19,000 mg/L design target | SCIRP 2015, section 2.1 (ref 7) |
| Aeration / air-scour duty | Set to control fouling on submerged modules; energy and membrane life are the main OPEX trade-offs | ScienceDirect 2024 review, highlights |
| Pretreatment | Screening, equalization, pH adjustment so the MBR sees a buffered feed | ScienceDirect 2024 review — listed as critical to country-level MBR success |
Two pieces of mechanical pretreatment typically sit upstream of the MBR tank itself: a rotary mechanical bar screen to protect the membrane from fibers and large solids, and an automatic chemical dosing skid for pH correction and nutrient balancing. Both are standard scope on a working pharma ETP.
Frequently Asked Questions
What effluent numbers can a pharmaceutical MBR guarantee?
Across the SCIRP 2015 review, a well-controlled MBR on pharmaceutical wastewater reports residual COD under 50 mg/L after greater than 99.5% removal, total N at 5–10 mg/L after 85–90% removal, and ammonia at 1.4–4.1 mg/L after 94.5–97.6% removal on a 72.8–92.4 mg/L feed. TSS and turbidity are driven close to zero by the membrane itself. These are operating-window values, not contractual guarantees, and they shift with influent variability across API,
Frequently Asked Questions
What effluent quality can an MBR reliably deliver on pharmaceutical wastewater?
Modern MBR systems for pharmaceutical applications consistently achieve BOD5 levels below 5 mg/L, TSS below 1 mg/L, and turbidity under 0.2 NTU. Total Nitrogen (TN) can be reduced to less than 10 mg/L through integrated pre-denitrification zones, while Total Phosphorus (TP) is typically maintained below 1 mg/L, provided proper chemical precipitation is integrated into the process.
Is MBR alone enough to meet pharmaceutical discharge limits, or do I need RO or advanced oxidation afterwards?
MBR is highly effective at removing bulk organics and suspended solids but is often insufficient for meeting stringent API-specific toxicity standards or recalcitrant COD limits. If discharge permits mandate the removal of trace pharmaceuticals or specific non-biodegradable compounds, MBR must be followed by Advanced Oxidation Processes (AOP) like UV/H2O2 or Ozonation, or Reverse Osmosis (RO) if total dissolved solids (TDS) reduction or water reuse is required.
How do I size an MBR for a cephalosporin or API plant — what HRT and MLSS should I specify?
For high-strength pharmaceutical streams like cephalosporin production, design for a Hydraulic Retention Time (HRT) of 18 to 36 hours to account for slow-degrading substrates. Specify a Mixed Liquor Suspended Solids (MLSS) concentration between 8,000 and 12,000 mg/L to maintain biomass stability; operating above 12,000 mg/L often leads to excessive viscosity and increased membrane scouring air requirements.
What does a packaged MBR system for a 6,000–8,000 m³/day pharma plant typically cost and how long does delivery take?
For a facility of this scale, capital expenditure for the MBR process equipment—including membrane skids, aeration blowers, and permeate pumps—typically ranges from $4.5 million to $7.5 million USD, excluding civil works and installation. Lead times for these systems currently range from 40 to 52 weeks, depending on the complexity of the control integration and the availability of specific membrane modules.
Which influent parameters should I send to an MBR supplier to get a defensible pharmaceutical effluent guarantee?
To receive a binding guarantee, provide the supplier with a comprehensive characterization including 24-hour flow-weighted composite samples for BOD5, COD (total and soluble), TOC, TKN, NH3-N, TP, and TSS. Additionally, you must specify the concentration of any recalcitrant solvents, inhibitory API concentrations, heavy metals, and the pH range, as these significantly impact membrane fouling rates and biological activity.
